The aggravating factors of hyperammonemia related to 5-fluorouracil infusion-A report of two cases

Auris Nasus Larynx

Volumn 35, Issue 2, 2008, Pages 295-299

  Kikuta, Shu ^a   Asakage, Takahiro ^a   Nakao, Kazunari ^a   Sugasawa, Masashi ^a   Kubota, Akatsuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 Fluorouracil; Hyperammonemia; Leukoencephalopathy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; CASE REPORT; CATABOLISM; CONSTIPATION; DRUG INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLUID THERAPY; HUMAN; HYPERAMMONEMIA; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; OROPHARYNX CARCINOMA; RISK FACTOR; SQUAMOUS CELL CARCINOMA; WEIGHT REDUCTION;

BRAIN DISEASES; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; HYPERAMMONEMIA; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS;

EID: 41549149037     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2007.04.012     Document Type: Article

References (12)

1. Mitchell R.B., Wagner J.E., Karp J.E., Watson A.J., Brusilow S.W., Rzepiorka D., et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 85 (1988) 662-667
2. Ohara S., Hayashi R., Hata S., Itoh N., Hanyu N., and Yamamoto K. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Acta Neuropathol (Berl) 96 (1998) 527-531
3. Chen J.S., Lin Y.C., Jan Y.Y., and Liau C.T. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs 12 (2001) 339-343
4. Lin Y.C., Chen J.S., Wang C.H., Wang H.M., Chang H.K., Liaul C.T., et al. Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 31 (2001) 605-609
5. Yeh K.H., and Cheng A.L. High-dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis and encephalopathy. Br J Cancer 75 (1997) 464-465
6. Liaw C.C., Wang H.M., Wang C.H., Yang T.S., Chen J.S., Chang H.K., et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10 (1999) 275-281
7. Pinedo H.M., and Peters G.J. Fluorouracil: biochemistry and pharmacology. J Clin Oncology 6 (1988) 1653-1664
8. Franco D.A., and Greenberg H.S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology 56 (2001) 110-112
9. Okeda R., Shibutani M., Matsuo T., Kuroiwa T., Shimokawa R., and Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the onofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol (Berl) 81 (1990) 66-73
10. Langer C.J., Hageboutros A., Kloth D.D., Roby D., and Shaer A.H. Acute encephalopathy attributed to 5-FU. Pharmacotherapy 16 (1996) 311-313
11. Blackburn G.L., Bintrian B.R., Maini B.S., Schlamm H.T., and Smith M.F. Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr 1 (1977) 11-22
12. Alan H., Joseph M., Robert E., and Alan S. The dynamic of ammonia metabolism in man. J Clin Invest 63 (1979) 449-460